论文部分内容阅读
目的观察奈达铂注射液联合紫杉醇注射液同步放化疗治疗晚期鼻咽癌的临床疗效。方法 75例晚期鼻咽癌患者随机分为对照组35例和试验组40例。2组均给予放疗,每次2 Gy,每周5次,5周为1个疗程。在放疗的同时对照组第1天静脉滴注顺铂60 mg·m~(-2),5-氟尿嘧啶600 mg·m~(-2),3周为1个疗程。试验组第1天静脉滴注顺铂60 mg·m~(-2),紫杉醇120 mg·m~(-2),奈达铂60mg·m~(-2),2周为1个疗程,共治疗4个疗程。比较2组患者的临床疗效及药物不良反应发生情况。结果治疗后,试验组总有效率为95.00%(38/40例),对照组为62.86%(22/35例),差异有统计学意义(P<0.05)。试验组疾病控制率为77.50%(31/40例),无远处转移率为75.00%(30/40例),5年生存率为82.50%(33/40例);对照组疾病控制率为54.29%(19/35例),无远处转移率为48.57%(17/35例),5年生存率为60.00%(21/35例),2组差异有统计学意义(P<0.05)。对照组出现白细胞减少2例,胃肠道反应2例,口腔黏膜反应1例,药物不良反应发生率为14.29%(5/35例);试验组出现白细胞减少1例,口腔黏膜反应1例,药物不良反应发生率为5.00%(2/40例),差异有统计学意义(P<0.05)。结论奈达铂与紫杉醇联合同步放化疗治疗晚期鼻咽癌的临床效果理想,安全性高。
Objective To observe the clinical efficacy of nedaplatin injection combined with paclitaxel injection concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods Seventy-five patients with advanced nasopharyngeal carcinoma were randomly divided into control group (35 cases) and experimental group (40 cases). Both groups were given radiotherapy, 2 Gy each time, 5 times a week, 5 weeks for a course of treatment. At the same time of radiotherapy, the control group received intravenous cisplatin 60 mg · m -2 and 5-fluorouracil 600 mg · m -2 on the first day, and one course of treatment was 3 weeks. On the first day of the experimental group, cisplatin 60 mg · m -2, paclitaxel 120 mg · m -2, nedaplatin 60 mg · m -2, A total of 4 courses of treatment. The clinical efficacy and adverse drug reactions of two groups were compared. Results After treatment, the total effective rate was 95.00% (38/40 cases) in the test group and 62.86% (22/35 cases) in the control group, the difference was statistically significant (P <0.05). The control rate of disease in experimental group was 77.50% (31/40 cases), no distant metastasis rate was 75.00% (30/40 cases), and the 5-year survival rate was 82.50% (33/40 cases). The control rate of disease in control group was 54.29% (19/35 cases), no distant metastasis rate was 48.57% (17/35 cases), 5-year survival rate was 60.00% (21/35 cases), the difference between the two groups was statistically significant (P0.05) . In the control group, there were 2 cases of leukopenia, 2 cases of gastrointestinal reaction, 1 case of oral mucosa reaction and 14.29% (5/35 cases) of adverse drug reactions. One case of leukopenia and 1 case of oral mucosa reaction were found in the test group, Adverse drug reaction rate was 5.00% (2/40 cases), the difference was statistically significant (P <0.05). Conclusion Nedaplatin and paclitaxel combined with concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma have satisfactory clinical effects and high safety.